Skip Navigation


Rheumatology Advance Access originally published online on July 28, 2009
Rheumatology 2009 48(10):1247-1253; doi:10.1093/rheumatology/kep158
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
48/10/1247    most recent
kep158v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Schipper, L. G.
Right arrow Articles by Van Riel, P. L. C. M.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Schipper, L. G.
Right arrow Articles by Van Riel, P. L. C. M.
Related Collections
Right arrow Pharmacology
Right arrow Rheumatoid Arthritis
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2009. Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved. For Permissions, please email: journals.permissions@oxfordjournals.org

Methotrexate therapy in rheumatoid arthritis after failure to sulphasalazine: to switch or to add?

Lydia G. Schipper1, Jaap Fransen1, Pilar Barrera1, Alfons A. den Broeder2 and Piet L. C. M. Van Riel1

1Department of Rheumatology, Radboud University Nijmegen Medical Centre and 2Department of Rheumatology, Sint Maartenskliniek Nijmegen, Nijmegen, The Netherlands.

Correspondence to: Lydia G. Schipper, Department of Rheumatology, Radboud University Nijmegen Medical Centre, PO Box 9101, NL-6500 HB, Nijmegen, The Netherlands. E-mail: LSchipper{at}reuma.umcn.nl


  Abstract

Objectives. MTX, either alone or in combination with SSZ, is effective in the treatment of RA. Trials have shown that, after SSZ failure, the addition of MTX to SSZ is more effective than a switch to MTX. Whether this is also the case in daily practice has not been analysed yet. In this study, we compared the efficacy of a switch to MTX monotherapy with that of the addition of MTX to SSZ in the daily clinical practice of RA patients who had failed SSZ monotherapy in the Nijmegen RA Inception Cohort.

Methods. For this study, 230 patients who failed to SSZ monotherapy were followed for up to 52 weeks. A total of 124 underwent a switch to MTX alone, whereas 106 patients received the combination of MTX and SSZ. The primary outcome measure was the mean change in the disease activity score (DAS28) after 24 weeks.

Results. Both treatment groups showed a significant decrease in DAS28 after 24 weeks, which was similar in both groups. Drug survival analysis showed that the chance to stop with a DMARD within 52 weeks was higher in the MTX–SSZ group (P <0.01).

Conclusions. In RA patients who failed to SSZ the clinical efficacy of a switch to MTX monotherapy was similar to that of the addition of MTX, suggesting that in daily clinical practice a switch to MTX is a good option for patients with an inadequate response to SSZ.

KEY WORDS: Rheumatoid arthritis, Combination drug therapy, Methotrexate, Sulphasalazine, Therapeutic use

Submitted 23 February 2009; revised version accepted 15 May 2009.
Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.